vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 1,369,863 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average price of $1.46 per share, for a total transaction of $1,999,999.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of VTVT opened at $1.60 on Thursday. vTv Therapeutics Inc has a 12-month low of $1.00 and a 12-month high of $3.50. The firm has a market capitalization of $81.74 million, a price-to-earnings ratio of -2.32 and a beta of -3.61. The stock’s 50-day moving average price is $1.46 and its 200 day moving average price is $1.45.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.69 million. On average, equities research analysts expect that vTv Therapeutics Inc will post -0.44 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in vTv Therapeutics stock. Wedbush Securities Inc. acquired a new stake in vTv Therapeutics Inc (NASDAQ:VTVT) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 25,100 shares of the biotechnology company’s stock, valued at approximately $39,000. Institutional investors and hedge funds own 6.12% of the company’s stock.

Several equities analysts recently issued reports on VTVT shares. Northland Securities restated a “buy” rating on shares of vTv Therapeutics in a research note on Thursday, October 31st. Zacks Investment Research upgraded vTv Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Friday, November 8th. ValuEngine upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of vTv Therapeutics in a research note on Friday, August 16th.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: What is a Swap?

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.